Positron has shipped its PET scanner hardware platform, the Posicam-HZL, to the National Institute of Radiological Sciences of Japan. The equipment will be marketed and distributed by Imatron-Japan. The center will use the Posicam-HZL in oncology
Positron has shipped its PET scanner hardware platform, the Posicam-HZL, to the National Institute of Radiological Sciences of Japan. The equipment will be marketed and distributed by Imatron-Japan.
The center will use the Posicam-HZL in oncology and cardiology research, said Dr. Katsuya Yoshida of Japan's Division of Advanced Technology for Medical Imaging. Imatron-Japan president Sachiko Kinoshita said she expects interest in PET scanners to increase in that country.
Imatron, a South San Francisco-based company that creates electron beam tomography scanners, has a 16% interest in Houston-based Positron.
Positron has reported an increase in revenue for first quarter 2000 (end March 31) of 200% over the same period last year. Revenue was $1.2 million in this period compared with revenue of $388,000 for first quarter 1999. The company ascribes the increase in revenue to the shipment of one Posicam system; it did not ship any Posicam systems in the first quarter of 1999. Positron reported a net loss of $157,000 in the first quarter of 2000, which it attributed to increased staff and related operation expenditures. This was compared to net income of $34,000 in the first quarter of 1999.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.